Status:
COMPLETED
Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
Lead Sponsor:
Asan Medical Center
Conditions:
Gastrointestinal Stromal Tumor(GIST)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To achieve optimal clinical outcomes with imatinib in GIST patients, it is crucial to maintain standard imatinib dose. Skin rash is a relatively common and sometimes severe adverse event of imatinib i...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age 18 years or older, at the time of acquisition of informed consent
- Histologically confirmed metastatic and/or advanced (unresectable or recurrent) GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene
- Patients with metastatic and/or advanced (unresectable or recurrent) GISTs, receiving imatinib as adjuvant or neo adjuvant, palliative chemotherapy for pre-or post- operations
- imatinib-associated severe skin rash which was defined as grade 3 skin rash or grade 2 skin rash with pruritus over grade 2
Exclusion
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2017
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT03440515
Start Date
August 1 2014
End Date
June 1 2017
Last Update
January 7 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.